Pipeline Biogen trims Apellis pipeline and R&D team after $5.6bn takeover Pharmaceutical TechnologyBiogen plans to pause or terminate investment in most of Apellis' legacy research programmes, while cutting some of its workforce.Immunology & InflammationRead full story pharminent June 29, 2026 (Last updated: June 29, 2026) Pharmaceutical Technology Biogen plans to pause or terminate investment in most of Apellis’ legacy research programmes, while cutting some of its workforce. Immunology & Inflammation Read full story Post navigation Previous: Viridian wins FDA approval for Lumvoa for thyroid eye diseaseNext: BridgeBio’s achondroplasia pill shows ‘compelling’ growth and body proportionality benefit Related Stories Pipeline Beyond GLP1s: The race for nextgen obesity drugs starts in the preclinical models pharminent September 2, 2026 Pipeline Bausch + Lomb advances dry eye disease drug to Phase 3 despite mid-stage fail pharminent August 25, 2026 Pipeline Chasing Dupixent, a biotech aims to make better antibody drugs for eczema pharminent August 11, 2026